| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Annals of Surgical Oncology, Vol 6, Issue 3 315-321, Copyright © 1999 by Society of Surgical Oncology
ARTICLES |
P. J. Borgstein, S. Meijer and P. J. van Diest
Department of Surgical Oncology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands.
BACKGROUND: In-transit metastases and satellite lesions are manifestations of locoregional cutaneous recurrence that are characteristic of malignant melanoma. They are the result of tumor cell emboli entrapped in the dermal lymphatics between the primary tumor and the regional lymph node basin. Histopathological features of lymphatic invasion were investigated to determine the possibility of predicting locoregional cutaneous metastases in melanoma patients. METHODS: In a prospective study, 258 patients with clinical stage I melanoma underwent wide local excision and sentinel node biopsy. Nodal metastases were found in 53 (21%) patients. Of 29 patients (11.2%) who had developed recurrences to date, 17 (6.6%) had locoregional cutaneous metastases. All surgical specimens were examined with particular attention to histopathological signs of lymphatic vascular invasion or microscopic satellites. RESULTS: Unequivocal signs of lymphatic invasion were observed in 14 of 258 patients (5.4%), and 13 (93%) of these patients subsequently developed in-transit metastases, after a median interval of 10 months. The primary melanoma was located on the extremities in seven patients. The median Breslow thickness was 2.5 mm, and 5 showed ulceration. In 244 of 258 patients (94.6%), there were no signs of lymphatic invasion. To date, only four patients (1.6%) have had a locoregional cutaneous recurrence, occurring after a median interval of 29 months. All four of these patients had ulcerative melanomas on an extremity, with a median thickness of 4.0 mm. The presence of lymphatic invasion was significantly related to early locoregional cutaneous relapse (P < .0001). CONCLUSIONS: Locoregional cutaneous recurrence appears to be highly predictable in the presence of histopathological signs of lymphatic invasion. Lymphatic invasion is an important prognostic parameter and should be included as a stratification criterion when selecting patients for adjuvant (locoregional) therapy.
This article has been cited by other articles:
 |
|
 |
|
  F. Niakosari, H. J. Kahn, D. McCready, D. Ghazarian, L. E. Rotstein, A. Marks, A. Kiss, and L. From Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration: Predictors of Sentinel Lymph Node Involvement in Primary Cutaneous Melanoma Arch Dermatol, April 1, 2008; 144(4): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kretschmer, I. Beckmann, K.-M. Thoms, C. Mitteldorf, H. P. Bertsch, and C. Neumann Factors Predicting the Risk of In-Transit Recurrence After Sentinel Lymphonodectomy in Patients With Cutaneous Malignant Melanoma Ann. Surg. Oncol., August 1, 2006; 13(8): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Thomas In Reply J. Clin. Oncol., June 20, 2006; 24(18): 2966 - 2967. [Full Text] [PDF]
|
|
|
|
|
|
T. M. Pawlik, M. I. Ross, M. M. Johnson, C. W. Schacherer, D. M. McClain, P. F. Mansfield, J. E. Lee, J. N. Cormier, and J. E. Gershenwald Predictors and Natural History of In-Transit Melanoma After Sentinel Lymphadenectomy Ann. Surg. Oncol., August 1, 2005; 12(8): 587 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. van Poll, J. F. Thompson, M. H. Colman, J. G. McKinnon, R. P. M. Saw, J. R. Stretch, R. A. Scolyer, and R. F. Uren A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma Ann. Surg. Oncol., August 1, 2005; 12(8): 597 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Pawlik, M. I. Ross, J. F. Thompson, A. M.M. Eggermont, and J. E. Gershenwald The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph Nodes J. Clin. Oncol., July 20, 2005; 23(21): 4588 - 4590. [Full Text] [PDF]
|
|
|
|
|
|
F. Niakosari, H. J. Kahn, A. Marks, and L. From Detection of Lymphatic Invasion in Primary Melanoma With Monoclonal Antibody D2-40: A New Selective Immunohistochemical Marker of Lymphatic Endothelium Arch Dermatol, April 1, 2005; 141(4): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Rossi, M. Foletto, S. Mocellin, P. Pilati, and M. Lise Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-{alpha} and Melphalan for Bulky In-Transit Melanoma Metastases Ann. Surg. Oncol., February 1, 2004; 11(2): 173 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G S Mijnhout, O S Hoekstra, A van Lingen, P J van Diest, H J Ader, A A Lammertsma, R Pijpers, S Meijer, and G J J Teule How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma J. Clin. Pathol., April 1, 2003; 56(4): 283 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.J.C.L.M. Vuylsteke, P.A.M. van Leeuwen, M.G. S. Muller, H.A. Gietema, D.R. Kragt, and S. Meijer Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results J. Clin. Oncol., March 15, 2003; 21(6): 1057 - 1065. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
